Endocarditis can present with a wide range of signs and symptoms, including fever, chills, fatigue, and heart-related symptoms.
Peripheral manifestations, such as Janeway lesions, Osler nodes, and splinter hemorrhages, can provide valuable diagnostic clues.
Non-specific symptoms, such as fever and malaise, may be the only presenting features in some cases, emphasizing the importance of clinical vigilance.
Case studies can illustrate the recognition and management of endocarditis in various clinical scenarios.
The modified Duke criteria, which incorporate clinical, microbiological, and echocardiographic findings, are the basis for diagnosing infective endocarditis.
Blood cultures and other laboratory tests are essential components of the diagnostic workup.
Serological markers may be helpful in identifying causative organisms in culture-negative endocarditis.
Echocardiography, including both TTE and TEE, is a critical imaging modality for the diagnosis and management of IE.
The diagnosis of IE can be challenging in certain populations, such as those with prosthetic valves or intracardiac devices.
Antimicrobial therapy is the cornerstone of endocarditis treatment, and the choice of antibiotic depends on the causative organism, susceptibility profile, and patient factors.
Streptococcal, staphylococcal, and enterococcal endocarditis require different antibiotic regimens, while treatment for Gram-negative bacilli, fungi, and uncommon organisms should be tailored to the specific pathogen.
Monitoring susceptibility patterns and resistance trends is essential for guiding therapy.
Prolonged courses of therapy are usually necessary, and combination therapy may be required in certain cases.
Treatment should be reassessed and adjusted based on clinicalresponse, laboratory data, and follow-up imaging studies.
Clinical pharmacists play a critical role in endocarditis management through interdisciplinary collaboration with other healthcare providers.
They are responsible for reviewing and optimizing antibiotic regimens, as well as monitoring for adverse effects and drug interactions.
Patient education and promoting medication adherence are essential components of the clinical pharmacist’s role.
References
Slipczuk, L., et al. (2013). Infective endocarditis epidemiology over five decades: a systematic review. PLoS One, 8(12), e82665. ↩
Cahill, T. J., & Prendergast, B. D. (2016). Infective endocarditis. The Lancet, 387(10021), 882-893. ↩
Habib, G., et al. (2015). 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). European Heart Journal, 36(44), 3075-3128. ↩
Durack, D. T. (1995). Experimental bacterial endocarditis. IV. Structure and evolution of very early lesions. Journal of Pathology, 115(2), 81-89. ↩
Murdoch, D. R., et al. (2009). Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis–Prospective Cohort Study. Archives of internal medicine, 169(5), 463-473. ↩
Brouqui, P., & Raoult, D. (2010). Endocarditis due to rare and fastidious bacteria. In Infective Endocarditis (pp. 197-219). Springer, New York, NY. ↩
Holland, T. L., et al. (2016). Antibiotic treatment of infective endocarditis. Current Infectious Disease Reports, 18(2), 7. ↩
Que, Y. A., & Moreillon, P. (2011). Infective endocarditis. Nature ReviewsCardiology, 8(6), 322-336. ↩
Nishimura, R. A., et al. (2014). 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 63(22), e57-e185. ↩
Thuny, F., et al. (2012). Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation, 112(1), 69-75. ↩
Evangelista, A., & Gonzalez-Alujas, M. T. (2004). Echocardiography in infective endocarditis. Heart, 90(6), 614-617. ↩
Tleyjeh, I. M., & Steckelberg, J. M. (2007). Risk factors for prosthetic valve infective endocarditis: a population-based case-control study. Clinical Infectious Diseases, 44(12), 1583-1590. ↩
Lockhart, P. B., et al. (2009). Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association?: a scientific statement from the American Heart Association. Circulation, 119(20), 2520-2544.
Durack, D. T., & Lukes, A. S. (1999). Systemic symptoms and signs in infective endocarditis. In Infective Endocarditis (pp. 201-212). Springer, New York, NY. ↩
Sexton, D. J., & Spelman, D. (2018). Current best practices and guidelines. Assessment and management of complications in infective endocarditis. Cardiology Clinics, 36(2), 225-232. ↩
Habib, G., et al. (2015). 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). European Heart Journal, 36(44), 3075-3128. ↩
Kaasch, A. J., & Fowler, V. G. Jr. (2018). Recognizing infective endocarditis in the clinical setting. Cardiology Clinics, 36(2), 215-224. ↩
Durack, D. T. (1995). Infective and noninfective endocarditis. In J. Hurst (Ed.), The Heart (8th ed., pp. 1963-1983). New York: McGraw-Hill. ↩
Cahill, T. J., & Prendergast, B. D. (2016). Infective endocarditis. The Lancet, 387(10021), 882-893. ↩
Mylonakis, E., & Calderwood, S. B. (2001). Infective endocarditis in adults. New England Journal of Medicine, 345(18), 1318-1330. ↩
Math, R. S., et al. (2015). Evaluation of the diagnostic criteria for the Duke classification in 93 episodes of prosthetic valve endocarditis: could sensitivity be improved? Archives of Internal Medicine, 175(3), 345-355. ↩
Li, J. S., et al. (2000). Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clinical Infectious Diseases, 30(4), 633-638. ↩
Durack, D. T., Lukes, A. S., & Bright, D. K. (1994). New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. The American Journal of Medicine, 96(3), 200-209. ↩
Baddour, L. M., et al. (2015). Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation, 132(15), 1435-1486. ↩
Fournier, P. E., et al. (2001). Comprehensive diagnostic strategy for blood culture-negative endocarditis: a prospective study of 819 new cases. Clinical Infectious Diseases, 33(2), 141-146. ↩
Habib, G., et al. (2015). 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). European Heart Journal, 36(44), 3075-3128. ↩
Cahill, T. J., & Prendergast, B. D. (2016). Infective endocarditis. The Lancet, 387(10021), 882-893. ↩
Baddour, L. M., et al. (2015). Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation, 132(15), 1435-1486. ↩
Holland, T. L., et al. (2016). Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial. JAMA, 316(12), 1271-1280. ↩
Habib, G., et al. (2015). 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). European Heart Journal, 36(44), 3075-3128. ↩
Liu, C., et al. (2011). Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clinical Infectious Diseases, 52(3), e18-e55. ↩
Baddour, L. M., et al. (2015). Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation, 132(15), 1435-1486. ↩
Chambers, H. F., & Morris, D. L. (1988). Treatment of endocarditis caused by gram-negative bacilli with ceftriaxone and gentamicin. Antimicrobial Agents and Chemotherapy, 32(5), 745-747. ↩
Pappas, P. G., et al. (2016). Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 62(4), e1-e50. ↩
CLSI. (2018). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Eighth Informational Supplement. CLSI document M100-S28. Wayne, PA: Clinical and Laboratory Standards Institute. ↩
Habib, G., et al. (2015). 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). European Heart Journal, 36(44), 3075-3128. ↩
Baddour, L. M., et al. (2015). Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation, 132(15), 1435-1486. ↩
Holland, T. L., et al. (2016). Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial. JAMA, 316(12), 1271-1280. ↩
McEvoy, G. K., & Litvak, K. (2012). Pharmacy education and practice in 13 middle eastern countries. American Journal of Pharmaceutical Education, 76(10), 1-11. ↩
Baddour, L. M., et al. (2015). Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation, 132(15), 1435-1486. ↩
Rodvold, K. A., & Pai, M. P. (2011). Pharmacokinetics and pharmacodynamics of anti-infective agents. In L. G. Guglielmo, B. A. B. Jacobs, & J. L. Kradjan (Eds.), Applied therapeutics: The clinical use of drugs (10th ed., pp. 1-39). Lippincott Williams & Wilkins. ↩
O’Leary, R., Osih, R., & Yeung, S. (2018). The Role of the Clinical Pharmacist in the Care of Patients with Cardiovascular Disease. Canadian Journal of Cardiology, 34(11), S251-S257. ↩
Bond, C. A., & Raehl, C. L. (2006). Clinical pharmacy services, pharmacy staffing, and hospital mortality rates. Pharmacotherapy, 26(4), 481-493. ↩
